You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 8,529,945


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,529,945 protect, and when does it expire?

Patent 8,529,945 protects AEMCOLO and is included in one NDA.

This patent has twenty-eight patent family members in twenty-one countries.

Summary for Patent: 8,529,945
Title:Oral antimicrobial pharmaceutical compositions
Abstract: The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.
Inventor(s): Ajani; Mauro (Milan, IT), Bozzella; Roberta (Milan, IT), Celasco; Giuseppe (Genoa, IT), Villa; Roberto (Lecco, IT)
Assignee: Cosmo Technologies Ltd. (Dublin, IE)
Application Number:13/616,582
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,529,945

Introduction

United States Patent 8,529,945, hereafter referred to as the '945 patent, is a patent that has been granted by the U.S. Patent and Trademark Office (USPTO). To analyze the scope and claims of this patent, it is essential to delve into the specifics of the patent document, the legal framework governing patents, and the broader patent landscape.

Patent Overview

The '945 patent typically includes several key sections:

  • Abstract: A brief summary of the invention.
  • Background of the Invention: Context and prior art related to the invention.
  • Summary of the Invention: A concise description of the invention.
  • Detailed Description of the Invention: An in-depth explanation of the invention, including drawings and examples.
  • Claims: The legal definitions of the invention for which the patentee seeks protection.

Claims Analysis

The claims section is the most critical part of a patent, as it defines the scope of the invention and what is protected by the patent.

Independent Claims

Independent claims are standalone claims that define the invention without referencing other claims. These claims are crucial because they set the broadest scope of protection for the invention.

Dependent Claims

Dependent claims build upon independent claims and narrow down the scope by adding additional limitations. These claims help to ensure that the patentee has a range of protection levels, from broad to specific.

Patent Scope

The scope of a patent is determined by the language of the claims. Here are some key aspects to consider:

Claim Language

The length and count of independent claims can significantly impact the patent scope. Research has shown that narrower claims, measured by claim length and count, are associated with a higher probability of grant and a shorter examination process[3].

Practical Applications

For a patent to be eligible, the claims must integrate judicial exceptions into practical applications. This means the claimed invention must offer concrete technological improvements or solve specific problems in the relevant field. For example, the 2024 USPTO guidance update on AI patents emphasizes the importance of showing how abstract ideas are applied in a way that provides clear benefits, such as improved accuracy in speech recognition systems[1].

Patent Landscape

The patent landscape includes the broader context of existing patents, patent applications, and legal precedents that can affect the validity and enforceability of a patent.

Prior Art and Novelty

The '945 patent must demonstrate novelty and non-obviousness over prior art. This involves showing that the invention is new and not an obvious extension of existing technology.

Inventorship

Correct determination of inventorship is crucial. The true and only inventors must be listed on the patent application. Incorrect or incomplete identification of inventors can lead to the patent being invalid or unenforceable[5].

Recent Case Law and Guidance

The '945 patent would need to comply with recent case law and guidance updates. For instance, the 2024 USPTO guidance on AI patents provides new examples and clarifies the process for determining patent eligibility, which could impact how claims are drafted and evaluated[1].

Examples and Analogies

To illustrate the importance of practical applications, consider the example from the 2024 USPTO guidance update:

"Claim 2 specifies that the separated audio components are used in a speech recognition system to improve the accuracy of voice commands in a hands-free environment. This provides a meaningful limit and integrates the judicial exception into a practical application, making the claim patent-eligible."[1]

This example highlights how specifying the use of separated audio components in a real-world application (speech recognition) transforms an abstract idea into a patent-eligible invention.

Statistical Insights

Research on patent scope has shown that patents with narrower claims tend to have a higher probability of being granted and undergo a shorter examination process. For example, a study found that the examination process tends to narrow the scope of patent claims, and this narrowing is more significant when the duration of examination is longer[3].

Key Takeaways

  • Claims Language: The scope of a patent is heavily dependent on the language of the claims. Independent and dependent claims must be carefully crafted to ensure broad yet specific protection.
  • Practical Applications: Claims must integrate judicial exceptions into practical applications to be patent-eligible.
  • Inventorship: Correct identification of inventors is crucial for the validity and enforceability of the patent.
  • Compliance with Recent Guidance: Patents must comply with recent case law and guidance updates, such as the 2024 USPTO guidance on AI patents.
  • Statistical Insights: Narrower claims are associated with a higher probability of grant and a shorter examination process.

FAQs

  1. What is the importance of independent claims in a patent? Independent claims are standalone claims that define the invention without referencing other claims. They set the broadest scope of protection for the invention.

  2. How does the 2024 USPTO guidance update impact AI-related patent claims? The update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. It emphasizes the integration of judicial exceptions into practical applications and includes new examples specifically tailored to AI technologies[1].

  3. Why is correct inventorship crucial in patent applications? Correct inventorship is essential because incorrect or incomplete identification of inventors can lead to the patent being invalid or unenforceable. The true and only inventors must be listed on the patent application[5].

  4. How do narrower claims affect the patent examination process? Research has shown that narrower claims are associated with a higher probability of grant and a shorter examination process. The examination process tends to narrow the scope of patent claims, especially when the duration of examination is longer[3].

  5. What role does recent case law play in patent eligibility? Recent case law, such as Federal Circuit decisions, is integrated into guidance updates to promote consistency and clarity in the application of patent eligibility criteria. This helps reflect the latest judicial thinking and ensures that patents comply with current legal standards[1].

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. U.S. Patent and Trademark Office (USPTO) | USAGov
  3. Patent Claims and Patent Scope - SSRN
  4. Search for patents - USPTO
  5. Determining Inventorship for US Patent Applications - Oregon State University

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,529,945

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Redhill AEMCOLO rifamycin sodium TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 DISCN Yes No 8,529,945 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,529,945

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI2004A1295Jun 25, 2004

International Family Members for US Patent 8,529,945

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1763339 ⤷  Subscribe 122019000048 Germany ⤷  Subscribe
European Patent Office 1763339 ⤷  Subscribe C201930053 Spain ⤷  Subscribe
European Patent Office 1763339 ⤷  Subscribe SPC/GB19/037 United Kingdom ⤷  Subscribe
Austria E392889 ⤷  Subscribe
Canada 2569683 ⤷  Subscribe
Canada 2628005 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.